In the past ten years, immunotherapy has made great progress in clinical practice. Single-target therapy cannot meet the needs of patients, so there are some bispecific antibodies or multi-target combination therapy drugs. Bintrafusp alfa (M7824) is a kind of bifunctional fusion protein, which consists of the extracellular domain of anti-programmed death ligand-1 (PD-L1) fused to human transforming growth factor-β (TGF-β) receptor II. Through targeting at both ends, M7824 can effectively and specifically bind to PD-L1 and TGF-β, ultimately increasing the anti-tumor activity of CD8⁺ T cells and NK cells. This article reviews the action mechanism, clinical studies and development prospects of M7824.